Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.

Early Breast Cancer Trialists’ Collaborative group (EBCTCG). · 2021

Read Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. by Early Breast Cancer Trialists’ Collaborative group (EBCTCG). (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8324484.txt.

Description

Early Breast Cancer Trialists’ Collaborative group (EBCTCG) pools trial data on trastuzumab for early HER2-positive breast cancer. The drug targets the HER2 protein's outer domain. Added to chemotherapy, it cuts recurrence and death, but can harm the heart.

The group gathered patient-level data from seven randomised trials. The pool held 13,864 women with operable breast cancer. Both node-negative and node-positive cases entered. Long-term gains were set against cause-specific deaths. Cardiac risk was weighed in the same frame. Such pooled work gives the firmest long view of a drug's worth. Operable, early-stage disease was the shared trial frame.

Catalog record

CREATOREarly Breast Cancer Trialists’ Collaborative group (EBCTCG).
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8324484

Browse the full library · About the Tower of Babel